Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)

NCT01429623 is registered in ClinicalTrials.gov with Avraham Pharmaceuticals Ltd as lead sponsor.

NCT NCT01429623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01429623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)
Lead sponsor
Avraham Pharmaceuticals Ltd
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2012
Completion date
September 30, 2016
Enrollment
210 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, mild cognitive impairment